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medications for the same indication are used concurrently. We
investigated whether concurrent utilization of controller asthma
medications in patients switching therapies differs between con-
troller medication classes and whether it may lead to signiﬁcant
biases in observed patterns of medication possession and inap-
propriate claims for long-term patient adherence. METHODS:
We used MPRs as a proxy measure of adherence to asthma
controller medications. Asthma controller utilization patterns
were investigated using the Pharmetrics Managed Care database
for the period April 2003 to March 2006. Asthma patients who
were exclusively on two of three major controller groups were
identiﬁed: inhaled corticosteroids (ICSs), ﬂuticasone/salmeterol
(FS), and leukotriene modiﬁers (LTMs). MPRs were calculated
for days of concurrent possession (DCPs) between last and ﬁrst
prescription recorded, as well as the proportion of days that were
covered by concurrent controller possession (CCPs). RESULTS:
Overall for the study population (n = 7260), 1328 patients had
prescriptions for LTMs and ICSs; 4871 for LTMs and FS; and
1061 for ICSs and FS. The mean CCPs were highest for persons
reporting prescriptions for both LTMs and FS (0.224). Lowest
CCP was for ICS and FS (0.023). DCP over the 3-year observa-
tion period was highest for persons with LTMs and FS (0.152 or
166 days) and lowest for those with ICSs and FS (0.009 or 10
days). CONCLUSION: The analysis points to a signiﬁcant
number of asthma patients using LTMs concurrently with
another controller medication. This occurs despite the lack of
clinical evidential support for concurrent utilization over an
extended period. Estimates of MPRs for controller therapies
based on prescription counts need to be corrected for concurrent
medication usage to avoid overstating therapy adherence.
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OBJECTIVE: To assess the correlation between health care uti-
lization after diagnosis of chronic obstructive pulmonary disease
(COPD) and controller therapies prescribed during the ﬁrst year
after diagnosis. METHODS: A cohort of 991 patients with initial
diagnosis of COPD between January 1, 2003 and December 31,
2004 were constructed from the Lovelace Patient Database.
Inclusion criteria included: ﬁrst diagnosis of COPD (ICD-9CM
491, 492, or 496), >1 year of pre and post-diagnosis observation,
and >1 pharmacy claim. Ethnicity was estimated using the
GUESS (Generally Useful Ethnicity Search System) program. Use
of controller therapy: ﬂuticasone propionate (FP), salmeterol
(SAL), ipratropium (IPR), ipratropium + albuterol (IPA), and
ﬂuticasone/salmeterol combination (FSC) was calculated for each
patient using Medication Possession Ratios (MPR), the mean
number of prescription ﬁlls in the year following diagnosis. Cor-
relations between controller therapy and albuterol use, outpa-
tient, and inpatient visits were assessed using Pearson correlation
coefﬁcients and Negative Binomial regression models controlling
for age, sex, and Hispanic ethnicity. RESULTS: The sample of
991 patients included 6.6% FP, 8.8% IPA, 3.6% IPR, 2.5% SAL,
8.1% FSC, and 77.5% non-controller. The sample was 51.9%
female, 24.9% estimated Hispanic ethnicity, and mean age was
68 years. Albuterol MPR was correlated with FP (r = 0.42,
p < 0.0001), IPA (r = 0.08, p = 0.007), IPR (r = 0.37, p <
0.0001), SAL (r = 0.12, p < 0.0001), and FSC (r = 0.33, p <
0.0001). No controllers were signiﬁcantly correlated with
outpatient visit use. No controllers were signiﬁcantly correlated
with albuterol MPR when controlling for sex, ethnicity, and
age. FSC MPR was the only controller that was negatively cor-
related with hospitalizations (-2.05, p = 0.04). CONCLUSION:
Patients with an initial diagnosis of COPD experienced less hos-
pitalizations with more FSC use during the ﬁrst year, suggesting
a duration-response relationship. Controller use was not signiﬁ-
cantly correlated with albuterol MPR or count of outpatient
visits after adjustment.
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OBJECTIVE: The 2007 Canadian Respiratory Disease Guide-
lines recommend that treatment be initiated with inhaled corti-
costeroids (ICS). An analysis of provincial drug claims data was
undertaken to determine the impact of Ontario’s restricted drug
access system relative to Alberta’s open public formulary on the
use of four types of medication to treat respiratory disease. These
consisted of low cost ICS and higher cost long-acting b2 agonists
(LABA), combination therapy ICS plus LABA (COMBO) and
leukotrienes (LTRA). METHODS: A retrospective 12-month
review of patients aged < 55 years who were treated under the
public and private payer systems in Ontario and Alberta were
analyzed for “ﬁrst use” of inhaled respiratory therapies. “First
use” was deﬁned as a patient who had no prior record in the
previous three years of any controller agent. Inter and intra
provincial utilization comparisons were undertaken and reported
as likelihood ratios (LR). RESULTS: Under the restricted Ontario
public formulary, ﬁrst use ICS was signiﬁcantly more likely over
LABA, COMBO and LTRA (LR = 1.9; 3.0 and 16.9: p < 0.001)
relative to private drug plans in the province. In contrast, there
was signiﬁcantly less ICS use over the more costly LABA in the
open Alberta public system (LR = 0.37; p < 0.001). Furthermore,
there was almost identical usage of ICS vs. COMBO and LTRA
between the Alberta public and private drug plans (LR = 0.91;
p = 0.057 and 1.56; p = 0.001). CONCLUSION: Formulary
restrictions that are in keeping with clinical practice guidelines
appear to be an effective method for promoting appropriate drug
use and containing formulary expenditures. However, the impact
of such restrictions on other health care resources such as hos-
pital admissions for poorly controlled respiratory disease is
unknown. Patient level research is needed to evaluate the total
impact of formulary restrictions on all aspects of the health care
system.
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OBJECTIVE: Despite the recommendations from national guide-
lines, under-use of controller medications and overuse of quick
relief medications persists amongst asthmatics. The main objec-
tive of this study was to determine the effects of health insurance,
prescription drug insurance and availability of peak ﬂow meter
on controller drug therapy not being used by asthmatic patients.
METHODS: Data for this study came from 2004 Medical
Expenditure Panel Survey (MEPS).Study population included all
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